The Molecular Therapeutics of Cancer Program (MTCP) is a "translational research" effort interfacing basic scientists with clinicians specializing in cancer diagnosis and treatment. The program has deep strengths in lung cancer research and has used this experience to catalyze additional research that links disease oriented teams and basic researchers. The MTCP also provides a major series of bridges through its interactions other Cancer Center Programs. The goals of the MTCP are to understand the molecular events (genetic and epigenetic) leading to cancer, as well as understanding the role of inter-individual genetic variation in developing and treating cancer, and use this information to provide a rationale basis for developing novel diagnostic, prevention, and therapeutic strategies. Specifically the MTCP seeks to: ? Understand the molecular pathogenesis of cancers with a focus on human tissues and model systems with a particular emphasis on lung cancer. This includes both description of the abnormalities and demonstrating their functional relevance as biologic, therapeutic and diagnostic targets. ? Develop new cancer imaging and nanotechnology tools to deliver novel imaging agents and therapeutics to highlight these targets in vivo in preclinical model and later in the clinic. ? Develop molecular therapeutics including those involving or combined with radiafion targeted at the abnormalities found in studies of the molecular pathogenesis as well as the identification and use of specific cell surface markers characteristic of certain cancers as therapeutic targets. ? Develop tumor molecular biomarkers that allow prediction of clinical behavior and response to specific treatments of individual patients so that treatment can be "personalized." ? Use advances in the other Cancer Center Programs (Chemistry and Cancer, Cancer Cell Networks, and Development and Cancer) to inform each of these prior themes in a way that is unique to the Simmons Cancer Center and that will provide synergy of research efforts and facilitate translation to the clinic at UTSW.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
United States
Zip Code
Wong, Mandy S; Wright, Woodring E; Shay, Jerry W (2014) Alternative splicing regulation of telomerase: a new paradigm? Trends Genet 30:430-8
Chau, Vincent; Lim, S Kyun; Mo, Wei et al. (2014) Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. Cancer Res 74:586-97
Iscla, Irene; Wray, Robin; Wei, Shuguang et al. (2014) Streptomycin potency is dependent on MscL channel expression. Nat Commun 5:4891
Fu, Peng; Johnson, Melissa; Chen, Hong et al. (2014) Carpatamides A-C, cytotoxic arylamine derivatives from a marine-derived Streptomyces sp. J Nat Prod 77:1245-8
Park, Jason Y; Gunpat, Joshua; Liu, Li et al. (2014) Red-shifted emission from 1,2-dioxetane-based chemiluminescent reactions. Luminescence 29:553-8
Gerber, David E; Laccetti, Andrew L; Xuan, Lei et al. (2014) Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst 106:
Yang, Liu; Kwon, Junghee; Popov, Yury et al. (2014) Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 146:1339-50.e1
Li, Biaoru; Ding, Lianghao; Yang, Chinrang et al. (2014) Characterization of transcription factor networks involved in umbilical cord blood CD34+ stem cells-derived erythropoiesis. PLoS One 9:e107133
Ludlow, Andrew T; Robin, Jerome D; Sayed, Mohammed et al. (2014) Quantitative telomerase enzyme activity determination using droplet digital PCR with single cell resolution. Nucleic Acids Res 42:e104
King, Kelly A; Gordon-Salant, Sandra; Pawlowski, Karen S et al. (2014) Hearing loss is an early consequence of Npc1 gene deletion in the mouse model of Niemann-Pick disease, type C. J Assoc Res Otolaryngol 15:529-41

Showing the most recent 10 out of 83 publications